Company profile
GOSSAMER BIO, INC.
NASDAQ:GOSSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SERALUTINIB | phase3 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04556383 | phase2 | terminated | 2020-10-19 | 2022-06-01 | GB004, Inc. | A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) |
| NCT03926793 | phase1 | completed | 2020-02-04 | 2021-05-05 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension |
| NCT05934526 | phase3 | completed | 2023-12-28 | 2025-11-27 | GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) |
| NCT07181382 | phase3 | suspended | 2026-02-01 | 2028-12-01 | GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
| NCT03956862 | phase2 | completed | 2019-05-16 | 2020-07-09 | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | GB001 in Adult Participants With Chronic Rhinosinusitis |
FDA applications (0)
No records yet.